Skip to main content
Collaboration Platform > Engineered Pseudomonas aeruginosa

Engineered Pseudomonas aeruginosa

Using synthetic biology, these engineered bacteria can perform many activities to include releasing medically important chemicals and killing cancer cells. Drs. Su, Guo, Samy, and Krishnamoorthy are developing these biotechnologies. The United States of America’s National Science Foundation (NSF) and Open Therapeutics funded a bacterial lytic biotechnology that, in vitro, demonstrates destroying cholesteatoma tumors as an adjunct, or replacement, to skull-based surgery.


We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is pushing forward research that ordinarily would not generate a public value while particularly helping underserved scientists to collaborate.

How open science helps researchers succeed
Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers. We review literature demonstrating that open research is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open research practices bring significant benefits to researchers relative to more traditional closed practices.